The Use of the UroShield Device in Patients With Indwelling Urinary Catheters

Nanovibronix200 enrolled

Overview

According to the Israeli Ministry of Health requirement, this study was designed to evaluate the efficacy of the UroShield system is patients that require urinary catheterization. This was designed to compare standard treatment (urinary catheter alone) with the UroShield treatment in occurrence of catheter associated Urinary Tract infection, pain, discomfort, Biofilm prevention and trauma.

This study is aimed at assessing the effectiveness of the NanoVibronix™ UroShield™ System in comparison to Urinary catheter alone in patients requiring urinary catheterization. 1. Primary objectives * To observe the effect of UroShield in reduction of patient's complaints relating to indwelling Urinary Catheters * Pain * Discomfort * To observe the effect of UroShield in the reduction/prevention of Biofilm * To observe the effect of UroShield on the occurrence of bacteriuria and/or UTI's on patients with Indwelling Urinary Catheters 2. Safety Objective To assess the safety parameters of the UroShield system 3. Secondary Objectives * To observe the effect of UroShield in reduction of Foley Catheter related pain medication in patients with Indwelling Urinary Catheters * To observe the effect of UroShield in reduction of antibiotic medication in patients with Indwelling Urinary Catheter * To observe the effect of UroShield on the clogging of Urinary Catheter when used chronically and the need to replace the catheter * To observe the effect of UroShield on the decrease of Tissue damage of patients with Indwelling Urinary Catheters by measuring cell count before and after removal of catheter

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

200

Conditions

Urinary Tract Infection

Interventions

UroSshieldDEVICE

Attachment of the UroShield device to the external part of the urinary catheter

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized patients age 18 years or older * Patients requiring or having catheterization for more than 24 hours * Patient able, agrees and signs the Informed Consent Form Exclusion Criteria: * Pregnant or breastfeeding women. Women of child bearing potential will perform a pregnancy test before inclusion into the study * Presence of any clinically relevant known urinary tract infection * Patient with condition who is not expected to survive the study period * Known HIV positive * Patient has any condition, which precludes compliance with study and/or device instructions. * Patient is currently participating in another clinical study. * Known allergy to latex

Locations (1)

Shaare Zedek Medical Center

Jerusalem, Israel

RECRUITING

Outcomes

Primary Outcomes

primary end points

Time frame: up to 14 days

Central Contacts

Ofer Shenfeld, MD

CONTACT

972-2-6555560 shenfeld@szmc.org.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.